Showing results (821-830 of 977) with videos related to

Sort By:
Pageof 98
Kidney International|February 1, 2017
Loss of executive function after dialysis initiation in adults with chronic kidney diseaseManjula Kurella Tamura, Eric Vittinghoff, Chi-Yuan Hsu, et al.
BMC Pregnancy and Childbirth|February 18, 2021
Fetal growth restriction in a cohort of migrants in GermanyJuliane Ankert, Tanja Groten, Mathias W Pletz, et al.
Frontiers in Oncology|May 10, 2021
Endogenous Retroviral-K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell CarcinomaVeronika Weyerer, Pamela L Strissel, Christine Stöhr, et al.
Bioorganicheskaia Khimiia|November 8, 2001
[Cleavage of RNA in hybrid duplexes by E. coli ribonuclease H. II. Substrate properties of nucleotides containing non-nucleotide linkers]P E Vorob'ev, I A Pyshnaia, D V Pyshnyĭ, et al.
Journal of the American Society of Nephrology : JASN|October 21, 2005
Cystatin C and subclinical brain infarctionStephen L Seliger, W T Longstreth, Ronit Katz, et al.
Infection Control and Hospital Epidemiology|October 24, 2018
Immediate impact of healthcare-facility-onset Clostridium difficile laboratory-identified events reporting methodology change on standardized infection ratiosCarlos E Figueroa Castro, Louis Palen, Carrie Johnson, et al.
Kidney International Reports|March 20, 2023
Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial ParticipantsKenneth R Hallows, Kaleab Z Abebe, Hui Li, et al.
Frontiers in Immunology|October 29, 2024
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevanceAnnalena Branz, Christian Matek, Fabienne Lange, et al.
Cellular and Molecular Life Sciences : CMLS|December 3, 2024
Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumorsKarthikeyan Subbarayan, Ahmed Al-Samadi, Helene Schäfer, et al.
Proteomics|July 2, 2003
Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapyBarbara Seliger, Matthias Menig, Rudolf Lichtenfels, et al.
Pageof 98